SCHEMBL3721174

SCHEMBL3721174

Cc1ccc(O)c(CCCc2cccc(N(C(C)C)C(C)C)c2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 2/20 0.39
ALOX15 P16050 2/20 0.39
AMY1A P0DUB6 1/20 0.37
HTR2C P28335 1/20 0.36
HTR2B P41595 1/20 0.36
PTGER1 P34995 1/20 0.36
PTGER4 P35408 1/20 0.36
PTGER3 P43115 1/20 0.36
PTGER2 P43116 1/20 0.36
HTT P42858 1/20 0.35
LMNA P02545 1/20 0.34
ESR1 P03372 1/20 0.34
CHRM2 P08172 1/20 0.34
CHRM4 P08173 1/20 0.34
CHRM5 P08912 1/20 0.34
MAPT P10636 1/20 0.34
CHRM1 P11229 1/20 0.34
KCNE1 P15382 1/20 0.34
CHRM3 P20309 1/20 0.34
PTGS1 P23219 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4190007 0.86 BACE1 (0.40) IGF1RALOX15MAPT
SCHEMBL722594 0.86 IGF1R (0.36) IGF1RALOX15
SCHEMBL11300811 0.85 IGF1R (0.35) IGF1RALOX15OPRK1
SCHEMBL2431823 0.83 CDK1 (0.35) IGF1RALOX15
SCHEMBL6473875 0.83 GRIN2D (0.41) ALOX15PTGER1PTGER4PTGER3PTGER2
SCHEMBL11295519 0.83 HTR2B (0.39) IGF1RALOX15HTR2BSLC6A4
SCHEMBL7758297 0.81 BACE1 (0.34) IGF1RALOX15ESR1
SCHEMBL5668562 0.81 DRD2 (0.39) IGF1RALOX15AMY1AHTR2CHTR2B
SCHEMBL725536 0.80 PTGER1 (0.43) ALOX15PTGER1PTGER4PTGER3PTGER2
SCHEMBL1355901 0.80 CYP4A11 (0.47) ALOX15HTTLMNAMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012098560-A2 PROCESS FOR THE PREPARATION OF MUSCARINIC RECEPTOR ANTAGONIST MSN LABORATORIES LIMITED (IN) 2012-07-26 WO claimed
WO-2012098560-A2 PROCESS FOR THE PREPARATION OF MUSCARINIC RECEPTOR ANTAGONIST MSN LABORATORIES LIMITED (IN) 2012-07-26 WO disclosed
EP-2398765-A1 IMPROVED PROCESS FOR THE PREPARATION OF (R)-2-(3-DIISOPROPYLAMINO)-1-PHENYLPROPYL)-4METHYLPHENOL AND SALTS THEREOF Pharmathen S.A. (GR) 2011-12-28 EP disclosed
WO-2010094292-A1 IMPROVED PROCESS FOR THE PREPARATION OF (R)-2-(3-DIISOPROPYLAMINO)-1-PHENYLPROPYL)-4METHYLPHENOL AND SALTS THEREOF PHARMATHEN S.A. (GR) 2010-08-26 WO disclosed
EP-2114972-A2 MONOPHOSPHATES AS MUTUAL PRODRUGS OF MUSCARINIC RECEPTOR ANTAGONISTS AND BETA-AGONISTS FOR THE TREATMENT OF COPD AND CHRONIC BRONCHITIS Gilead Sciences, Inc. (US) 2009-11-11 EP disclosed
EP-2016042-A1 PROCESS FOR PREPARING TOLTERODINE OR ITS SALT AND SYNTHETIC INTERMEDIATE Estechpharma Co. Ltd. (KR) 2009-01-21 EP disclosed
WO-2008076269-A2 MONOPHOSPHATES AS MUTUAL PRODRUGS OF MUSCARINIC RECEPTOR ANTAGONISTS AND β-AGONISTS FOR THE TREATMENT OF COPD AND CHRONIC BRONCHITIS GILEAD SCIENCES, INC. (US) 2008-06-26 WO disclosed
WO-2007126217-A1 PROCESS FOR PREPARING TOLTERODINE OR ITS SALT AND SYNTHETIC INTERMEDIATE ESTECHPHARMA CO., LTD. (KR) 2007-11-08 WO disclosed
EP-1299342-A1 METHOD FOR PRODUCING 3,3-DIARYLPROPYLAMINES SCHWARZ PHARMA AG (DE) 2003-04-09 EP disclosed
WO-2002004399-A1 METHOD FOR PRODUCING 3,3-DIARYLPROPYLAMINES SCHWARZ PHARMA AG (DE) 2002-01-17 WO disclosed